MLTX · MoonLake Immunotherapeutics

MoonLake Immunotherapeutics achieved a critical regulatory milestone with the positive final pre-BLA meeting on April 1, 2026, where the FDA aligned with the company on BLA submission plans for sonelokimab in hidradenitis suppurativa (HS). Key agreements include using MIRA trial data to establish substantial evidence of effectiveness, full inclusion of VELA-TEEN adolescent data for labeling patients aged 12+, and safety data pooling from VELA-1/2 trials. The proposed label highlights MIRA's superior ~43% HiSCR75 response rate and ~29 percentage point delta-to-placebo at week 12, positioning sonelokimab as potentially best-in-class. No gaps were identified, enabling BLA submission by end-September 2026 and potential Priority Review decision by end-November 2026, with U.S. launch targeted for H2 2027 if approved. Financially, Q1 2026 R&D expenses held steady at $54.5M versus $56.0M in Q4 2025, reflecting ongoing clinical investments. G&A rose to $15.5M from $9.2M due to $4.8M accelerated expense from voluntary stock option cancellations. Strong balance sheet with $357.9M in cash equivalents supports operations through 2027, bolstered by up to $400M non-dilutive debt from Hercules Capital. A catalyst-rich pipeline includes Q2 VELA 52-week HS data, mid-2026 Phase 3 readouts in PsA (IZAR-1) and adolescent HS (VELA-TEEN), and Q4 IZAR-2 PsA data, enhancing near-term value inflection potential for investors.